High Gene Expression Predicts Response to Chemotherapy and Prognosis of High-grade Serous Ovarian Cancer Patients

Overview

Journal J Int Med Res

Publisher Sage Publications

Specialty General Medicine

Date 2022 Nov 11

PMID 36366735

Authors

Xiao-Fei Li

Hai-Bo Zhang

Yan Huo

Affiliations

Soon will be listed here.

Abstract

Objective: High-grade serous ovarian cancer (HGSOC) is a deadly malignancy. Homeobox protein A9 () is linked with serous papillary histotype differentiation, and inappropriate expression is a step in ovarian cancer that induces aberrant differentiation. This study aimed to reveal the significance of in HGSOC.

Methods: mRNA and protein expression were examined by quantitative PCR and immunohistochemistry, respectively. The chi-square test was used to evaluate associations between expression and clinical characteristics. The prognostic value of was calculated by the Kaplan-Meier method. The Kaplan-Meier Plotter database was used to assess the prognostic value of .

Results: The mRNA and protein expression of were significantly upregulated in chemotherapy-resistant HGSOC compared with chemotherapy-sensitive HGSOC. The chi-square test showed that high expression was significantly related with grade, clinical stage, and residual disease. High expression was significantly associated with poor prognosis. The Kaplan-Meier Plotter database further confirmed these results. Cox hazard regression showed that high expression was an independent prognostic factor for survival in HGSOC patients.

Conclusion: This study showed that expression was associated with chemotherapy resistance and poor outcomes in HGSOC patients. High expression might be a prognostic indicator for HGSOC.

Citing Articles

HOXA9 and CD163 potentiate pancreatic ductal adenocarcinoma progression.

Hemida A, Ahmed M, Tantawy M Diagn Pathol. 2024; 19(1):141.

PMID: 39462379 PMC: 11514874. DOI: 10.1186/s13000-024-01563-5.

HOXA9 versus HOXB9; particular focus on their controversial role in tumor pathogenesis.

Hjazi A, Jasim S, Al-Dhalimy A, Bansal P, Kaur H, Qasim M J Appl Genet. 2024; 65(3):473-492.

PMID: 38753266 DOI: 10.1007/s13353-024-00868-x.

HOXA9 transcription factor is a double-edged sword: from development to cancer progression.

Shenoy U, Adiga D, Alhedyan F, Kabekkodu S, Radhakrishnan R Cancer Metastasis Rev. 2023; 43(2):709-728.

PMID: 38062297 PMC: 11156722. DOI: 10.1007/s10555-023-10159-2.

References

Goncalves C, Xavier-Magalhaes A, Pojo M, Oliveira A, Correia S, Reis R . Transcriptional profiling of HOXA9-regulated genes in human glioblastoma cell models. Genom Data. 2015; 5:54-8. PMC: 4583997. DOI: 10.1016/j.gdata.2015.05.010. View

Sun Q, Zhang S, Zhao J, Han X, Wang H, Sun M . HIF-1α or HOTTIP/CTCF Promotes Head and Neck Squamous Cell Carcinoma Progression and Drug Resistance by Targeting HOXA9. Mol Ther Nucleic Acids. 2020; 20:164-175. PMC: 7068198. DOI: 10.1016/j.omtn.2019.12.045. View

Matulonis U, Sood A, Fallowfield L, Howitt B, Sehouli J, Karlan B . Ovarian cancer. Nat Rev Dis Primers. 2016; 2:16061. PMC: 7290868. DOI: 10.1038/nrdp.2016.61. View

El Bairi K, Amrani M, Kandhro A, Afqir S . Prediction of therapy response in ovarian cancer: Where are we now?. Crit Rev Clin Lab Sci. 2017; 54(4):233-266. DOI: 10.1080/10408363.2017.1313190. View

Sun M, Song C, Huang H, Frankenberger C, Sankarasharma D, Gomes S . HMGA2/TET1/HOXA9 signaling pathway regulates breast cancer growth and metastasis. Proc Natl Acad Sci U S A. 2013; 110(24):9920-5. PMC: 3683728. DOI: 10.1073/pnas.1305172110. View

Montavon C, Gloss B, Warton K, Barton C, Statham A, Scurry J . Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol. 2011; 124(3):582-8. DOI: 10.1016/j.ygyno.2011.11.026. View

Cheng W, Liu J, Yoshida H, Rosen D, Naora H . Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med. 2005; 11(5):531-7. DOI: 10.1038/nm1230. View

Xylinas E, Hassler M, Zhuang D, Krzywinski M, Erdem Z, Robinson B . An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer. Biomolecules. 2016; 6(3). PMC: 5039423. DOI: 10.3390/biom6030037. View

Adamaki M, Lambrou G, Athanasiadou A, Vlahopoulos S, Papavassiliou A, Moschovi M . HOXA9 and MEIS1 gene overexpression in the diagnosis of childhood acute leukemias: Significant correlation with relapse and overall survival. Leuk Res. 2015; 39(8):874-82. DOI: 10.1016/j.leukres.2015.04.012. View

10.

Ko S, Barengo N, Ladanyi A, Lee J, Marini F, Lengyel E . HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Invest. 2012; 122(10):3603-17. PMC: 3461910. DOI: 10.1172/JCI62229. View

11.

Costa B, Smith J, Chen Y, Chen J, Phillips H, Aldape K . Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. Cancer Res. 2010; 70(2):453-62. PMC: 2849935. DOI: 10.1158/0008-5472.CAN-09-2189. View

12.

Kelly Z, Michael A, Butler-Manuel S, Pandha H, Morgan R . HOX genes in ovarian cancer. J Ovarian Res. 2011; 4:16. PMC: 3179923. DOI: 10.1186/1757-2215-4-16. View

13.

He W, Guo Y, Yang G, Lai H, Sun T, Zhang Z . CHD1L promotes EOC cell invasiveness and metastasis via the regulation of METAP2. Int J Med Sci. 2020; 17(15):2387-2395. PMC: 7484650. DOI: 10.7150/ijms.48615. View

14.

Alvarado-Ruiz L, Martinez-Silva M, Torres-Reyes L, Pina-Sanchez P, Ortiz-Lazareno P, Bravo-Cuellar A . HOXA9 is Underexpressed in Cervical Cancer Cells and its Restoration Decreases Proliferation, Migration and Expression of Epithelial-to-Mesenchymal Transition Genes. Asian Pac J Cancer Prev. 2016; 17(3):1037-47. DOI: 10.7314/apjcp.2016.17.3.1037. View

15.

Pontikakis S, Papadaki C, Tzardi M, Trypaki M, Sfakianaki M, Koinis F . Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy. Pharmacogenomics J. 2016; 17(6):506-514. DOI: 10.1038/tpj.2016.63. View

16.

Ko S, Naora H . Adaptation of ovarian cancer cells to the peritoneal environment: Multiple mechanisms of the developmental patterning gene . Cancer Cell Microenviron. 2015; 1(6):e379. PMC: 4437227. View

17.

Eisenhauer E . Real-world evidence in the treatment of ovarian cancer. Ann Oncol. 2017; 28(suppl_8):viii61-viii65. DOI: 10.1093/annonc/mdx443. View

18.

Lai M, Liu G, Li R, Bai H, Zhao J, Xiao P . Hsa_circ_0079662 induces the resistance mechanism of the chemotherapy drug oxaliplatin through the TNF-α pathway in human colon cancer. J Cell Mol Med. 2020; 24(9):5021-5027. PMC: 7205783. DOI: 10.1111/jcmm.15122. View

19.

Wang J, Yuan Z . Gambogic acid sensitizes ovarian cancer cells to doxorubicin through ROS-mediated apoptosis. Cell Biochem Biophys. 2013; 67(1):199-206. DOI: 10.1007/s12013-013-9534-7. View

20.

Guan J, Darb-Esfahani S, Richter R, Taube E, Ruscito I, Mahner S . Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium. J Cancer Res Clin Oncol. 2019; 145(4):1063-1073. DOI: 10.1007/s00432-019-02877-4. View